Krka, d. d., Novo mesto is informing the public that its subsidiary Krka Sverige AB, Sweden (hereafter Krka Sverige) has received the decision of the Appeal Court in Oslo in the proceeding for issuing temporary injunction.

The Appeal Court in Oslo has rejected the appeal filed by Krka Sverige against the first instance decision by which the court has temporarily injuncted Krka Sverige from importing and selling products containing esomeprazole in Norway, upon request filed by AstraZeneca AB, Sweden and its subsidiary AstraZeneca A/S (hereinafter collectively referred as AstraZeneca).

The proceeding for alleged infringement of the patent which covers optically pure esomeprazole, at Oslo Commercial Court continues. Krka Sverige believes it will prove that the patent is not infringed.

Krka Sverige has also received the decision of the District Court in Stockholm in the proceeding for issuing temporary injunction for esomeprazole in Sweden. The court has rejected the motion by AstraZeneca for temporary injunction.

European patent which covers optically pure esomeprazole has been revoked by the European Patent Office.

Krka published the announcement concerning the litigation in Norway on 15 December 2010.